ERBB2 and bladder transitional cell carcinoma: RC48-ADC (disitamab vedotin), conjugating the anti-HER2 antibody hertuzumab to monomethyl auristatin E (MMAE)17,18, had activity in patients with HER2-amplified or -mutated BlCa that failed chemotherapy19–22.